The stock of Medican Enterprises Inc [MDCN] was up 38.46% at its previous close as it traded at $0.0018. In comparison to the 30-day average volume of 1.03B, the volume of the stock reached 1.95B. The stock value of the company has averaged between $0.0001 and $0.0040 over the last 52 weeks.
Medican Enterprises Inc [MDCN] has every intention of fulfilling its obligations of filing and reporting on time. In order to renew the Company’s registration with the Nevada Department of Commerce, two institutional investors contributed funds to its resident agent.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
- Two of the Best Pharmaceutical Stocks to Watch for in 2021
- 3 Best Gene Therapy Stocks for long-term Investment
February 25, 2021, this corporate update by Medican Enterprises Inc. (OTC Pink: MDCN) serves to apprise all stakeholders of the latest developments.
In July 2019, Medican signed a deal with Immediate Properties LLC in which Ken Williams was required to step down from all positions within three months. Dana Belle was immediately named interim CEO and director.
Investing and developing residential and commercial real estate is the specialty of Immediate Properties. A key aspect of the Company’s success is the strategic relationship the company has built with top equity suppliers, such as individual, commercial and institutional sources. Immediate Properties’ relationships with these banks and institutions have enabled us to do more than find and acquire income-producing properties.
A number of technology companies are developing drugs that are likely to cure diseases, making biotech stocks lucrative for investors hoping for a cure.